ANXA5 and neoplasm: Using EGFR as a positive surface protein control, we found that 15–25% of both EGFR surface+ and PRL3 surface+ “live” tumor cells were viable (Annexin-V−), whereas the remaining population were in early stages of apoptosis (Annexin-V+; Supplementary Fig. 3b, 3c).